nivolumab

Description: Nivolumab (trade name Opdivo; other names: BMS-936558; ONO-4538; MDX-1106; BMS 936558; ONO 4538; MDX 1106; BMS936558; ONO4538; MDX1106) is a programmed death receptor-1 (PD-1) blocking antibody that is used to treat advanced (metastatic) non-small cell lung cancer. Nivolumab is used as a first line treatment for inoperable or metastatic melanoma in combination with ipilimumab if the cancer does not have a mutation in BRAF, as a second-line treatment following treatment with ipilimumab and if the cancer has a mutation in BRAF, with a BRAF inhibitor, as a second-line treatment for squamous non-small cell lung cancer, and as a second-line treatment for renal cell carcinoma. Nivolumab has recently been approved for small cell lung cancer.

References: Cancer Immunol Res. 2014 Sep; 2(9):846-56.